Meropenem Qilu

Meropenem, the active ingredient in Meropenem Qilu, is a carbapenem presented as an injectable for intravesical use. It belongs to the beta‑lactam class and provides broad‑spectrum bactericidal activity against Gram‑negative and Gram‑positive organisms, including resistant strains. It is indicated for serious infections such as complicated urinary tract infections, intra‑abdominal infections, skin and soft‑tissue infections, and nosocomial pneumonia in hospitalized patients and requires prescription.

GNH USA supplies Meropenem Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a carbapenem antibiotic used to treat infections caused by susceptible bacteria in various organ systems.

Complicated urinary tract infections: effective in eradicating Gram‑negative and Gram‑positive pathogens causing severe cystitis and pyelonephritis. Intra‑abdominal infections: achieves bacterial clearance in peritonitis, abscesses, and postoperative intra‑abdominal sepsis. Skin and soft‑tissue infections: provides rapid bactericidal activity against cellulitis, wound infections, and necrotizing fasciitis. Nosocomial pneumonia: treats hospital‑acquired and ventilator‑associated pneumonia caused by resistant organisms.

Meropenem may be associated with a range of adverse reactions, most of which are dose‑related or infusion‑related.

Common Side Effects: - Nausea - Diarrhea - Infusion site phlebitis

Serious or Rare Side Effects: - Seizures, particularly in patients with renal dysfunction - Clostridioides difficile‑associated colitis - Anaphylactic or severe hypersensitivity reactions

When prescribing Meropenem, clinicians should consider several safety measures.

Renal function: adjust dose in patients with impaired renal function. Seizure risk: monitor patients with a history of CNS disorders or receiving high doses. Allergy: avoid in individuals with known hypersensitivity to carbapenems or other β‑lactams. Pregnancy: use only if benefit outweighs potential risk; category B. Concurrent antibiotics: consider potential for additive nephrotoxicity when combined with other nephrotoxic agents. Store at ambient temperature: keep in original container, protect from light and moisture.

Meropenem can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Valproic acid: carbapenems can reduce serum valproate levels, risking breakthrough seizures. - Probenecid: may increase meropenem plasma concentrations, enhancing toxicity. - Other carbapenems: concurrent use may increase risk of neurotoxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxic potential; monitor renal function. - Loop diuretics: may affect renal clearance of meropenem; adjust dosing as needed. - Warfarin: meropenem may alter INR; monitor coagulation parameters.